Innovations In Clinical Neuroscience

NOV-DEC 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: https://innovationscns.epubxp.com/i/924986

Contents of this Issue

Navigation

Page 71 of 83

72 ICNS INNOVATIONS IN CLINICAL NEUROSCIENCE November-December 2017 • Volume 14 • Number 11–12 C O M M E N T A R Y Psychiatr Scand. 2016;133(6):436–444. 8. Østergaard SD, Foldager L, Mors O, et al. The validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. Schizophr Bull. 2017 Jun 1. 9. Fleischhacker WW. The usefulness of rating scales in patients with schizophrenia. Acta Psychiatr Scand 2016;133(6):435. 10. Hochstrasser L, Borgwardt S, Lambert M, et al. Association of Positive and Negative Syndrome Scale short forms with global functioning and quality of life. Acta Psychiatr Scand. 2016;134(6):563–565. 11. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl). 1996;124(1- 2):168–175. 12. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry. 1997;154(6):782–791. 13. Bech P. Clinical Psychometrics. Oxford, UK: Wiley- Blackwell; 2012. 14. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. 15. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449. 16. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013. 17. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624–629. 18. Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37(2):300–305. 19. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item Negative Symptom Assessment. J Psychiatr Res. 1993;27(3):253–258. 20. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329. 21. Guy W. Clinical Global Impressions Scale. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare pub no (AMD) 76-338, NIMH, Rockville, MD, USA; 1976. 22. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci. 2011;13(2):155–172. 23. Guo T, Xiang YT, Xiao L, et al. Measurement- based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry. 2015;172(10):1004–1013. ICNS

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - NOV-DEC 2017